Dickkopf-1 Expression as a Predicting Factor for Bone Metastasis in Breast Cancer

Limba, Faruly Wijaya S.; Yulian, Erwin Danil; Kartini, Diani; Andinata, Bob; Tjahjadi, Hartono; Vidiawati, Dhanasari

doi:10.4999/uhod.204540

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These common mechanisms are also referred to as crosstalk between BC and bone cells, which promotes both TME and an osteoporotic microenvironment [ 126 ]. Another parallel between OP and BC is provided by the dysregulation of the Wnt pathway, which may be down-regulated by BC cells through synthesis and secretion of the Wnt antagonist DKK-1 [ 127 ], thereby inhibiting intrinsic bone regeneration and indirectly enhancing osteoclast-activating pathways such as NF-κB and RANK/RANKL, contributing to osteolysis in BC patients [ 128 ] ( Figure 5 ).…”

Section: Epigenetic Changes As Key Driving Factor Of Breast Cancer An...mentioning

confidence: 99%

Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol

Meyer,

Brockmueller,

Buhrmann

et al. 2024

Nutrients

View full text Add to dashboard Cite

Breast cancer (BC) is currently one of the most common cancers in women worldwide with a rising tendency. Epigenetics, generally inherited variations in gene expression that occur independently of changes in DNA sequence, and their disruption could be one of the main causes of BC due to inflammatory processes often associated with different lifestyle habits. In particular, hormone therapies are often indicated for hormone-positive BC, which accounts for more than 50–80% of all BC subtypes. Although the cure rate in the early stage is more than 70%, serious negative side effects such as secondary osteoporosis (OP) due to induced estrogen deficiency and chemotherapy are increasingly reported. Approaches to the management of secondary OP in BC patients comprise adjunctive therapy with bisphosphonates, non-steroidal anti-inflammatory drugs (NSAIDs), and cortisone, which partially reduce bone resorption and musculoskeletal pain but which are not capable of stimulating the necessary intrinsic bone regeneration. Therefore, there is a great therapeutic need for novel multitarget treatment strategies for BC which hold back the risk of secondary OP. In this review, resveratrol, a multitargeting polyphenol that has been discussed as a phytoestrogen with anti-inflammatory and anti-tumor effects at the epigenetic level, is presented as a potential adjunct to both support BC therapy and prevent osteoporotic risks by positively promoting intrinsic regeneration. In this context, resveratrol is also known for its unique role as an epigenetic modifier in the regulation of essential signaling processes—both due to its catabolic effect on BC and its anabolic effect on bone tissue.

show abstract

Section: Epigenetic Changes As Key Driving Factor Of Breast Cancer An...mentioning

confidence: 99%

Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol

Meyer,

Brockmueller,

Buhrmann

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

Dickkopf-1 Expression as a Predicting Factor for Bone Metastasis in Breast Cancer

Cited by 1 publication

References 0 publications

Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol

Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol

Contact Info

Product

Resources

About